Multiple myeloma, gammopathies

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: RFWD2 is a high-risk gene in multiple myeloma.
Fig. 2: RFWD2 promotes MM cellular proliferation and drug-resistance by regulating P27 degradation.


  1. 1.

    Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    CAS  Article  Google Scholar 

  2. 2.

    Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.

    CAS  Article  Google Scholar 

  3. 3.

    Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489–99.

    CAS  Article  Google Scholar 

  4. 4.

    Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.

    CAS  Article  Google Scholar 

  5. 5.

    Balsas P, Galan-Malo P, Marzo I, Naval J. Bortezomib resistance in a myeloma cell line is associated to PSMbeta5 overexpression and polyploidy. Leuk Res. 2012;36:212–8.

    CAS  Article  Google Scholar 

  6. 6.

    Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561–84.

    CAS  Article  Google Scholar 

  7. 7.

    Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, et al. NEDD8 inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma. Clin Cancer Res. 2015;21:5532–42.

    CAS  Article  Google Scholar 

  8. 8.

    Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303.

    CAS  Article  Google Scholar 

  9. 9.

    Kato S, Ding J, Pisck E, Jhala U, Du K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem. 2008;283:35464–73.

    CAS  Article  Google Scholar 

  10. 10.

    Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, et al. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015;14:2265–73.

    CAS  Article  Google Scholar 

  11. 11.

    Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.

    CAS  Article  Google Scholar 

  12. 12.

    Pernet CR, Wilcox RR, Rousselet GA. Robust correlation analyses: false positive and power validation using a new open source matlab toolbox. Front Psychol. 2013;3:606.

    Article  Google Scholar 

  13. 13.

    Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543–53.

    CAS  Article  Google Scholar 

  14. 14.

    Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109:4995–5001.

    CAS  Article  Google Scholar 

  15. 15.

    Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26:2406–13.

    CAS  Article  Google Scholar 

Download references


This work was supported by National Key Research and Development Program-precision medicine sub-program 2016YFC0905900 (to YY); National Natural Science Foundation of China 81970196 (to CG), 81670200 (to YY); The Priority Academic Program Development of Jiangsu Higher Education Institutions for Chinese Medicine.

Author information



Corresponding author

Correspondence to Ye Yang.

Ethics declarations

Conflict of interest

No potential conflicts of interest were disclosed.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gu, C., Lu, T., Wang, W. et al. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia (2020).

Download citation